BRAVO Study Examines Cost and Recurrence Outcomes of Blue Light Cystoscopy in NMIBC - Stephen Williams
Stephen Williams
Ashish Kamat speaks with Stephen Williams about the BRAVO study, a propensity-matched retrospective analysis of 311 blue light versus 311 white light cystoscopy patients with NMIBC in the VA Healthcare System from 1997 to 2021.
Enfortumab Vedotin Plus Pembrolizumab FDA-Approved for Cisplatin-Ineligible MIBC - Matthew Galsky
Matthew Galsky
Elizabeth Plimack speaks with Matthew Galsky about the FDA approval of enfortumab vedotin (PADCEV®) with pembrolizumab (Keytruda®) for cisplatin-ineligible muscle-invasive bladder cancer based on the KEYNOTE-905/EV-303 trial.
